COMMENTARY

Restructuring, Divestment Progress in Wake of Drug Pricing Overhaul

By Takashi Ebisawa February 20, 2019
A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

To read the full story

COMMENTARY

By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Rejii Anasako

While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…